Parallel Screening of Wild-Type and Drug-Resistant Targets for Anti-Resistance Neuraminidase Inhibitors

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Hsu, Kai Cheng ^a   Hung, Hui Chen ^b   Horng, Jim Tong ^c   Fang, Ming Yu ^b   Chang, Chun Yu ^b   Li, Ling Ting ^a   Chen, I Jung ^b   Chen, Yun Chu ^c   Chou, Ding Li ^c   Chang, Chun Wei ^b   Hsieh, Hsing Pang ^b   Yang, Jinn Moon ^a   Hsu, John T A ^a,b  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; REMAZOL BRILLIANT BLUE R; SIALIDASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; HYDROGEN BOND; IC 50; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INSECT CELL; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN STRUCTURE; VIRUS MUTANT; VIRUS STRAIN; WILD TYPE;

ANTHRAQUINONES; ANTIVIRAL AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, VIRAL; GENOTYPE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MUTATION; NEURAMINIDASE; PANDEMICS;

EID: 84874225444     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056704     Document Type: Article

References (77)

1. Service RF (1997) Medicine- Researchers seek new weapon against the flu. Science 275: 756-757.
2. Pennisi E, (1995) Infectious-Disease- Planning for the Next Flu Pandemic. Science 270: 1916-1917.
3. Neumann G, Noda T, Kawaoka Y, (2009) Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459: 931-939.
4. Rambaut A, Holmes E, (2009) The early molecular epidemiology of the swine-origin A/H1N1 human influenza pandemic. PLoS Currents 1: RRN1003.
5. Bharathi A, Ghosh A, Whalen WA, Yoon JH, Pu R, et al. (1997) The human RAE1 gene is a functional homologue of Schizosaccharomyces pombe rae1 gene involved in nuclear export of Poly(A)(+) RNA. Gene 198: 251-258.
6. Hsieh HP, Hsu JTA, (2007) Strategies of development of antiviral agents directed against influenza virus replication. Current Pharmaceutical Design 13: 3531-3542.
7. Palese P, Schulman JL, Bodo G, Meindl P, (1974) Inhibition of influenza and parainfluenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA). Virology 59: 490-498.
8. Seto JT, Rott R, (1966) Functional significance of sialidose during influenza virus multiplication. Virology 30: 731-737.
9. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, et al. (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363: 418-423.
10. Li WX, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, et al. (1998) Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrobial Agents and Chemotherapy 42: 647-653.
11. Babu YS, Chand P, Bantia S, Kotian P, Dehghani A, et al. (2000) BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. Journal of Medicinal Chemistry 43: 3482-3486.
12. Antiviral drugs for prophylaxis and treatment of influenza. Medical Letter on Drugs and Therapeutics 47: 93-95.
13. de Jong MD, Thanh TT, Khanh TH, Hien VM, Smith GJD, et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. New England Journal of Medicine 353: 2667-2672.
14. Carr J, Ives J, Kelly L, Lambkin R, Oxford J, et al. (2002) Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Research 54: 79-88.
15. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV, (2010) Recovery of a Multidrug-Resistant Strain of Pandemic Influenza A 2009 (H1N1) Virus Carrying a Dual H275Y/I223R Mutation from a Child after Prolonged Treatment with Oseltamivir. Clinical Infectious Diseases 51: 983-984.
16. Hurt AC, Holien JK, Barr IG, (2009) In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrobial Agents and Chemotherapy 53: 4433-4440.
17. Ravindranathan KP, Mandiyan V, Ekkati AR, Bae JH, Schlessinger J, et al. (2010) Discovery of Novel Fibroblast Growth Factor Receptor 1 Kinase Inhibitors by Structure-Based Virtual Screening. Journal of Medicinal Chemistry 53: 1662-1672.
18. Steele RM, Benedini F, Biondi S, Borghi V, Carzaniga L, et al. (2009) Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma. Bioorganic & Medicinal Chemistry Letters 19: 6565-6570.
19. Ferri N, Corsini A, Bottino P, Clerici F, Contini A, (2009) Virtual Screening Approach for the Identification of New Rac1 Inhibitors. Journal of Medicinal Chemistry 52: 4087-4090.
20. Duesberg P, Stindl R, Hehlmann R, (2000) Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. Proceedings of the National Academy of Sciences of the United States of America 97: 14295-14300.
21. Palese P, Young JF, (1982) Variation of Influenza-A, Influenza-B, and Influenza-C viruses. Science 215: 1468-1474.
22. Chen LM, Perlina A, Lee CJ, (2004) Positive selection detection in 40,000 human immunodeficiency virus (HIV) type 1 sequences automatically identifies drug resistance and positive fitness mutations in HIV protease and reverse transcriptase. Journal of Virology 78: 3722-3732.
23. Chen YF, Hsu KC, Lin SR, Wang WC, Huang YC, et al. (2010) SiMMap: a web server for inferring site-moiety map to recognize interaction preferences between protein pockets and compound moieties. Nucleic Acids Research 38: W424-W430.
24. Hsu KC, Cheng WC, Chen YF, Wang HJ, Li LT, et al. (2012) Core site-moiety maps reveal inhibitors and binding mechanisms of orthologous proteins by screening compound libraries. PLoS One 7: e32142.
25. Yang JM, Chen CC, (2004) GEMDOCK: a generic evolutionary method for molecular docking. Proteins: Structure, Function, and Bioinformatics 55: 288-304.
26. Ewing TJ, Makino S, Skillman AG, Kuntz ID, (2001) DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. Journal of Computer-Aided Molecular Design 15: 411-428.
27. Kramer B, Rarey M, Lengauer T, (1999) Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins 37: 228-241.
28. Jones G, Willett P, Glen RC, Leach AR, Taylor R, (1997) Development and validation of a genetic algorithm for flexible docking. Journal of Molecular Biology 267: 727-748.
29. Yang JM, Shen TW, (2005) A pharmacophore-based evolutionary approach for screening selective estrogen receptor modulators. Proteins-Structure Function and Bioinformatics 59: 205-220.
30. Yang JM, Chen YF, Tu YY, Yen KR, Yang YL, (2007) Combinatorial computational approaches to identify tetracycline derivatives as flavivirus inhibitors. PLoS One 2: e428.
31. Chin KH, Lee YC, Tu ZL, Chen CH, Tseng YH, et al. (2010) The cAMP receptor-like protein CLP is a novel c-di-GMP receptor linking cell-cell signaling to virulence gene expression in Xanthomonas campestris. Journal of Molecular Biology 396: 646-662.
32. Yang MC, Guan HH, Yang JM, Ko CN, Liu MY, et al. (2008) Rational design for crystallization of beta-lactoglobulin and vitamin D-3 complex: revealing a secondary binding site Crystal Growth & Design. 8: 4268-4276.
33. Stoll V, Stewart KD, Maring CJ, Muchmore S, Giranda V, et al. (2003) Influenza neuraminidase inhibitors: Structure-based design of a novel inhibitor series. Biochemistry 42: 718-727.
34. Maring CJ, Stoll VS, Zhao C, Sun M, Krueger AC, et al. (2005) Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors. Journal of Medicinal Chemistry 16: 3980-3990.
35. Kim CU, Lew W, Williams MA, Liu HT, Zhang LJ, et al. (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. Journal of the American Chemical Society 119: 681-690.
36. Kim CU, Lew W, Williams MA, Wu HW, Zhang LJ, et al. (1998) Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. Journal of Medicinal Chemistry 41: 2451-2460.
37. Xu X, Zhu X, Dwek RA, Stevens J, Wilson IA, (2008) Structural characterization of the 1918 influenza virus H1N1 neuraminidase. Journal of Virology 82: 10493-10501.
38. Luo M, (2006) Structural biology: antiviral drugs fit for a purpose. Nature 443: 37-38.
39. Varghese JN, Colman PM, van Donkelaar A, Blick TJ, Sahasrabudhe A, et al. (1997) Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases. Proceedings of the National Academy of Sciences of the United States of America 94: 11808-11812.
40. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, et al. (2008) Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453: 1258-1261.
41. Hung HC, Tseng CP, Yang JM, Ju YW, Tseng SN, et al. (2009) Aurintricarboxylic acid inhibits influenza virus neuraminidase. Antiviral Research 81: 123-131.
42. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, et al. (2006) Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. Journal of Virology 80: 8787-8795.
43. Colman PM, (1994) Influenza-Virus Neuraminidase- Structure, Antibodies, and Inhibitors. Protein Science 3: 1687-1696.
44. Hsu KC, Chen YF, Lin SR, Yang JM, (2011) iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis. BMC Bioinformatics 12Suppl 1: S33.
45. Smee DF, Huffman JH, Morrison AC, Barnard DL, Sidwell RW, (2001) Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrobial Agents and Chemotherapy 45: 743-748.
46. Shih SR, Horng JT, Poon LLM, Chen TC, Yeh JY, et al. (2010) BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses. Journal of Antimicrobial Chemotherapy 65: 63-71.
47. Meindl P, Bodo G, Palese P, Schulman J, Tuppy H, (1974) Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 58: 457-463.
48. Yang L, Wang KJ, Chen JA, Jegga AG, Luo H, et al. (2011) Exploring Off-Targets and Off-Systems for Adverse Drug Reactions via Chemical-Protein Interactome- Clozapine-Induced Agranulocytosis as a Case Study. PLoS Computational Biology 7: e1002016.
49. Sawatdichaikul O, Hannongbua S, Sangma C, Wolschann P, Choowongkomon K, (2012) In silico screening of epidermal growth factor receptor (EGFR) in the tyrosine kinase domain through a medicinal plant compound database. Journal of Molecular Modeling 18: 1241-1254.
50. Kitchen DB, Decornez H, Furr JR, Bajorath J, (2004) Docking and scoring in virtual screening for drug discovery: Methods and applications. Nature Reviews Drug Discovery 3: 935-949.
51. Lyne PD, (2002) Structure-based virtual screening: an overview. Drug Discovery Today 7: 1047-1055.
52. Tanrikulu Y, Schneider G, (2008) Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening. Nature Reviews Drug Discovery 7: 667-677.
53. Wang YL, Xiao JW, Suzek TO, Zhang J, Wang JY, et al. (2009) PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Research 37: W623-W633.
54. Irwin JJ, Shoichet BK, (2005) ZINC- A free database of commercially available compounds for virtual screening. Journal of Chemical Information and Modeling 45: 177-182.
55. Dandapani S, Marcaurelle LA, (2010) Accessing new chemical space for 'undruggable' targets. Nature Chemical Biology 6: 861-863.
56. Lipinski C, Hopkins A, (2004) Navigating chemical space for biology and medicine. Nature 432: 855-861.
57. van der Vries E, Stelma FF, Boucher CAB, (2010) Emergence of a Multidrug-Resistant Pandemic Influenza A (H1N1) Virus. New England Journal of Medicine 363: 1381-1382.
58. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 21: 2237-2246.
59. Smith J, (2005) Erlotinib: Small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clinical Therapeutics 27: 1513-1534.
60. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New England Journal of Medicine 352: 786-792.
61. Moscona A, (2005) Oseltamivir resistance-disabling our influenza defenses. The New England Journal of Medicine 353: 2633-2636.
62. Pizzorno A, Abed Y, Boivin G, (2011) Influenza Drug Resistance. Seminars in Respiratory and Critical Care Medicine 32: 409-422.
63. Browning CH, (1967) Proflavine and acriflavine. British Medical Journal 2: 111.
64. Nunziante M, Kehler C, Maas E, Kassack MU, Groschup M, et al. (2005) Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication. Journal of Cell Science 118: 4959-4973.
65. Meissner PE, Mandi G, Witte S, Coulibaly B, Mansmann U, et al. (2005) Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]. Malaria Journal 4: 45.
66. Mandi G, Witte S, Meissner P, Coulibaly B, Mansmann U, et al. (2005) Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso. Tropical Medicine & International Health 10: 32-38.
67. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, et al. (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443: 45-49.
68. Shindyalov IN, Bourne PE, (1998) Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. Protein Engineering 11: 739-747.
69. Arnold K, Bordoli L, Kopp J, Schwede T, (2006) The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22: 195-201.
70. Morris GM, Goodsell DS, Huey R, Olson AJ, (1996) Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. Journal of Computer-Aided Molecular Design 10: 293-304.
71. Yang J-M, Chen Y-F, Shen T-W, Kristal BS, Hsu DF, (2005) Consensus scoring criteria for improving enrichment in virtual screening. Journal of Chemical Information and Modeling 45: 1134-1146.
72. Wood JM, Robertson JS, (2007) Reference viruses for seasonal and pandemic influenza vaccine preparation. Influenza 1: 5-9.
73. Cory AH, Owen TC, Barltrop JA, Cory JG, (1991) Use of an Aqueous Soluble Tetrazolium Formazan Assay for Cell-Growth Assays in Culture. Cancer Communications 3: 207-212.
74. Jonges M, Liu WM, van der Vries E, Jacobi R, Pronk I, et al. (2010) Influenza Virus Inactivation for Studies of Antigenicity and Phenotypic Neuraminidase Inhibitor Resistance Profiling. Journal of Clinical Microbiology 48: 928-940.
75. Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB, (1979) Fluorometric Assay of Neuraminidase with a Sodium (4-Methylumbelliferyl-Alpha-D-N-Acetylneuraminate) Substrate. Analytical Biochemistry 94: 287-296.
76. Jedrzejas MJ, Singh S, Brouillette WJ, Laver WG, Air GM, et al. (1995) Structures of Aromatic Inhibitors of Influenza-Virus Neuraminidase. Biochemistry 34: 3144-3151.
77. Venkatramani L, Bochkareva E, Lee JT, Gulati U, Graeme Laver W, et al. (2006) An epidemiologically significant epitope of a 1998 human influenza virus neuraminidase forms a highly hydrated interface in the NA-antibody complex. Journal of Molecular Biology 356: 651-663.